8RZW

A fragment-based inhibitor of SHP2


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.02 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.216 
  • R-Value Observed: 0.218 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Fragment-Based Discovery of Allosteric Inhibitors of SH2 Domain-Containing Protein Tyrosine Phosphatase-2 (SHP2).

Day, J.E.H.Berdini, V.Castro, J.Chessari, G.Davies, T.G.Day, P.J.St Denis, J.D.Fujiwara, H.Fukaya, S.Hamlett, C.C.F.Hearn, K.Hiscock, S.D.Holvey, R.S.Ito, S.Kandola, N.Kodama, Y.Liebeschuetz, J.W.Martins, V.Matsuo, K.Mortenson, P.N.Muench, S.Nakatsuru, Y.Ochiiwa, H.Palmer, N.Peakman, T.Price, A.Reader, M.Rees, D.C.Rich, S.J.Shah, A.Shibata, Y.Smyth, T.Twigg, D.G.Wallis, N.G.Williams, G.Wilsher, N.E.Woodhead, A.Shimamura, T.Johnson, C.N.

(2024) J Med Chem 67: 4655-4675

  • DOI: https://doi.org/10.1021/acs.jmedchem.3c02118
  • Primary Citation of Related Structures:  
    8RZW, 8RZY, 8S01, 8S04, 8S06, 8S07, 8S0H, 8S0I, 8S0J, 8S0K, 8S0O, 8S0P, 8S0Q, 8S0S

  • PubMed Abstract: 

    The ubiquitously expressed protein tyrosine phosphatase SHP2 is required for signaling downstream of receptor tyrosine kinases (RTKs) and plays a role in regulating many cellular processes. Genetic knockdown and pharmacological inhibition of SHP2 suppresses RAS/MAPK signaling and inhibit the proliferation of RTK-driven cancer cell lines. Here, we describe the first reported fragment-to-lead campaign against SHP2, where X-ray crystallography and biophysical techniques were used to identify fragments binding to multiple sites on SHP2. Structure-guided optimization, including several computational methods, led to the discovery of two structurally distinct series of SHP2 inhibitors binding to the previously reported allosteric tunnel binding site (Tunnel Site). One of these series was advanced to a low-nanomolar lead that inhibited tumor growth when dosed orally to mice bearing HCC827 xenografts. Furthermore, a third series of SHP2 inhibitors was discovered binding to a previously unreported site, lying at the interface of the C-terminal SH2 and catalytic domains.


  • Organizational Affiliation

    Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Tyrosine-protein phosphatase non-receptor type 11
A, B
537Homo sapiensMutation(s): 0 
Gene Names: PTPN11PTP2CSHPTP2
EC: 3.1.3.48
UniProt & NIH Common Fund Data Resources
Find proteins for Q06124 (Homo sapiens)
Explore Q06124 
Go to UniProtKB:  Q06124
PHAROS:  Q06124
GTEx:  ENSG00000179295 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ06124
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.02 Å
  • R-Value Free: 0.272 
  • R-Value Work: 0.216 
  • R-Value Observed: 0.218 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 46.063α = 90
b = 212.634β = 97.16
c = 55.987γ = 90
Software Package:
Software NamePurpose
XDSdata reduction
XDSdata reduction
Aimlessdata scaling
Aimlessdata scaling

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2024-03-20
    Type: Initial release
  • Version 1.1: 2024-04-10
    Changes: Database references